IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.

INAB | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: EMPIRE STATE BUILDING, 10118 NEW YORK
Website:: https://www.in8bio.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies. A pioneer in the field, IN8BIO was the first company to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400 (Phase 2 for glioblastoma), INB-200 (Phase 1 for glioblastoma), and INB-100 (Phase 1 for leukemia), complemented by a portfolio of preclinical programs. The company's stated mission is to achieve "CANCER ZERO" by developing next-generation treatments for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Adicet Bio, Inc. Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.	United States of America	ACET
Adlai Nortye Ltd. Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.	United States of America	ANL
ADMA BIOLOGICS, INC. End-to-end biopharma making plasma-derived biologics for immune-compromised patients.	United States of America	ADMA
Adverum Biotechnologies, Inc. Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.	United States of America	ADVM
Advicenne Develops and commercializes therapies for rare renal diseases for patients of all ages.	France	ALDVI
AegirBio AB Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.	Sweden	AEGIR
Aelis Farma Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.	France	AELIS
AEON Biopharma, Inc. Developing therapeutic neurotoxins for medical conditions like migraines and cervical dystonia.	United States of America	AEON
AFC-HD AMS Life Science Co.,Ltd. An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.	Japan	2927
AGENUS INC Develops antibodies, cell therapies & adjuvants to harness the immune system against cancer.	United States of America	AGEN